Clonal Evolution

McDermott, Gao, & Murphy (2015) — Chromothriptic Cure of WHIM Syndrome: Implications for Bone Marrow Transplantation

Properties1
tagslow-evidence, genomic-alterations, clinical

7 min read

Bibliographic Reference

McDermott, D. H., Gao, J.-L., & Murphy, P. M. (2015). Chromothriptic cure of WHIM syndrome: Implications for bone marrow transplantation. Rare Diseases, 3(1), e1073430. https://doi.org/10.1080/21675511.2015.1073430

Note: This is an Addendum to McDermott, D. H., Gao, J. L., Liu, Q., Siwicki, M., Martens, C., Jacobs, P., … & Murphy, P. M. (2015). Chromothriptic cure of WHIM syndrome. Cell, 160(4), 686–699. The addendum summarizes the Cell paper and extends its translational implications for bone marrow transplantation.

Core Argument

A 59-year-old female (WHIM-09) with WHIM syndrome — a rare primary immunodeficiency caused by gain-of-function CXCR4 mutations — underwent spontaneous phenotypic reversion as an adult. Chromothripsis on one copy of chromosome 2 deleted 164 genes including the mutant CXCR4^R334X allele in a single hematopoietic stem cell (HSC). This corrected HSC repopulated the bone marrow without conditioning, an unprecedented event in transplantation biology. Mouse competitive repopulation experiments demonstrated that Cxcr4 haploinsufficiency (Cxcr4^+/o) alone confers a selective advantage over both wild-type and WHIM-mutant (Cxcr4^+/S338X) HSCs, suggesting CXCR4 gene dosage is the primary driver. The authors propose that genome editing to inactivate the mutant CXCR4 allele in autologous HSCs could enable conditioning-free bone marrow transplantation as a general cure strategy for WHIM syndrome, and that pharmacologic CXCR4 blockade might broadly enhance HSC engraftment.

Methods

This addendum is a commentary/perspective piece with no new primary data. It summarizes the original Cell paper (McDermott et al., 2015, Cell 160, 686–699) which included:

  • Human component: Single case study (N = 1). Genomic and hematologic analysis of patient WHIM-09, including somatic mosaicism characterization showing the CXCR4^R334X mutation was absent in myeloid and erythroid lineages but present in lymphoid lineage and epithelial cells.
  • Mouse experiments: Competitive bone marrow repopulation assays using Cxcr4^+/S338X (WHIM model) and Cxcr4^+/o (haploinsufficiency) donor cells transplanted into irradiated recipients. Both whole bone marrow and lineage-depleted cells were tested.
  • Clinical follow-up: Patient WHIM-09 had been healthy with CXCR4-haploinsufficient HSCs for at least 20 years at time of reporting.

Limitation: Key methodological details (irradiation dose, cell numbers, competitive ratios, sample sizes, chimerism measurement methods, statistical tests) are absent from the addendum and gated behind the Cell paper. The mouse experiments used irradiated recipients, which does not directly test the conditioning-free engraftment scenario proposed for clinical translation.

Key Findings

  • A single chromothriptic event on one copy of chromosome 2 in a hematopoietic stem cell deleted 164 genes including the disease-causing mutant CXCR4^R334X allele, producing a somatic genetic mosaic in patient WHIM-09. The mutant allele was absent from myeloid and erythroid lineages but present in lymphoid lineage and epithelial cells. (McDermott et al., 2015, Addendum)
  • The corrected HSC repopulated the bone marrow without any exogenous conditioning, an event the authors describe as “quite unprecedented” in transplantation biology. The patient has remained healthy with CXCR4-haploinsufficient HSCs for at least 20 years. (McDermott et al., 2015, Addendum)
  • Mouse competitive repopulation experiments demonstrated that Cxcr4^+/o (haploinsufficient) bone marrow cells outcompete both wild-type and WHIM-mutant (Cxcr4^+/S338X) cells in irradiated recipients, consistent with CXCR4 haploinsufficiency alone — rather than any of the other 163 deleted genes — being sufficient to confer the selective engraftment advantage. (McDermott et al., 2015, Addendum)
  • The authors propose that genome editing (using “molecular scissors”) to inactivate the mutant CXCR4 allele in autologous HSCs could recapitulate the WHIM-09 outcome as a general cure strategy, potentially without conditioning. A provisional patent on CXCR4 knockdown as a method to enhance HSC engraftment was filed. (McDermott et al., 2015, Addendum)

Concepts Introduced or Used

  • Chromothripsis as therapeutic mechanism — the same catastrophic genomic shattering typically associated with cancer can, in rare cases, produce a curative deletion of a disease-causing allele. Connects to chromothripsis and hopeful-monster.
  • Somatic rescue via chromothripsis — spontaneous correction of a germline mutation by a catastrophic somatic event. Distinct from typical revertant mosaicism (which usually involves point mutations, intragenic recombination, or gene conversion). Related to somatic genetic rescue in other hematopoietic disorders.
  • CXCR4 gene dosage and HSC fitness — CXCR4 signaling shows a non-monotonic dose-response curve for HSC competitive fitness: null is perinatal lethal, WHIM hyperfunction impairs engraftment, haploinsufficiency may optimize niche dynamics.
  • Conditioning-free HSC engraftment — the concept that altering HSC competitive fitness (rather than ablating the incumbent population) could enable donor HSC engraftment without cytotoxic conditioning.
  • WHIM syndrome (Warts, Hypogammaglobulinemia, Infections, Myelokathexis) — autosomal dominant immunodeficiency caused by gain-of-function CXCR4 C-terminal truncation mutations. Myelokathexis = neutrophil retention in bone marrow due to hyperactive CXCR4 signaling preventing egress.

Entities Referenced

  • CXCR4 — CXC chemokine receptor 4; receptor for CXCL12 (SDF-1); regulates HSC retention in bone marrow niche, neutrophil egress, and lymphocyte trafficking. Gain-of-function mutations cause WHIM syndrome. Also an HIV coreceptor and implicated in cancer metastasis.
  • CXCL12 / SDF-1 — ligand for CXCR4; produced by bone marrow stromal cells; anchors HSCs in the niche.
  • Plerixafor (Mozobil / AMD3100) — FDA-approved small-molecule CXCR4 antagonist; used for HSC mobilization prior to apheresis for BMT. Also under investigation as WHIM syndrome therapy.
  • Patient WHIM-09 — the index patient, a 59-year-old female; the same individual described in the original 1964 case reports of myelokathexis by Krill et al. and Zuelzer. Her case spans from the first descriptions of the syndrome to its spontaneous chromothriptic cure.
  • CCR5 — CC chemokine receptor 5; comparison drawn to the “Berlin patient” cured of HIV via homozygous CCR5Δ32 bone marrow transplantation.

Limitations

As stated by the authors and identified by reviewers:

  • Single case (N = 1). All human inferences rest on one patient. WHIM syndrome shows variable expressivity, and the unique features of WHIM-09 (age, disease duration, specific CXCR4 mutation, bone marrow history) may not generalize.
  • 164-gene confound. The chromothriptic deletion removed 163 genes besides CXCR4. The mouse experiment isolates Cxcr4 but does so in a different species, genetic background, and after irradiation — it cannot rule out contributions from other deleted genes in the human context.
  • Conditioning mismatch. The mouse competitive repopulation experiments used irradiated recipients. The proposed clinical application envisions conditioning-free engraftment. This critical experiment (competitive advantage without conditioning) is not tested.
  • Revertant mosaicism literature not engaged. Spontaneous genetic reversion in hematopoietic disorders (ADA-SCID, Wiskott-Aldrich syndrome, Fanconi anemia) was documented before 2015. The authors do not situate their case within this literature, inflating the novelty claim.
  • Genome editing proposal underspecified. No discussion of delivery method, editing efficiency in HSCs, allele-specific targeting requirements, off-target risks, or the narrow window between haploinsufficient and null editing.
  • Patent conflict of interest. The authors filed a provisional patent on CXCR4 knockdown for HSC engraftment. This creates a structural incentive to overstate the CXCR4-specific mechanism and underweight alternative explanations. Disclosure is present but the influence on claimed conclusions is not discussed.
  • Monoclonal hematopoiesis risk not addressed. WHIM-09 has essentially monoclonal hematopoiesis from a single HSC. The long-term risk of clonal evolution toward hematologic malignancy (analogous to CHIP) is not discussed.
  • No quantitative selection parameters. The selective advantage is described qualitatively. The selection coefficient s — which could be estimated from time-to-fixation and HSC niche size — is not reported.

Relevance to Clonal Evolution

This case is a pure demonstration of clonal evolution operating in a non-malignant human somatic tissue. Every element of the Darwinian framework is present: a somatic mutation (chromothriptic deletion) produced heritable variation in a single HSC → that variant had a large fitness advantage over incumbent HSCs → it expanded clonally and swept to near-fixation in the hematopoietic compartment → the clinical outcome (cure) was the manifestation of a complete selective sweep. The case reveals that somatic evolution is value-neutral: the same Darwinian process that drives cancer progression can, when the selective landscape favors normal function over malignancy, produce therapeutic outcomes.

The estimated selection coefficient for the corrected HSC — inferred from complete repopulation of the HSC compartment (Ne ~ 10⁴–10⁵) without conditioning — is likely on the order of s ≈ 0.01–0.1 per cell division, among the largest fitness advantages documented for a single genetic change in human somatic tissue, exceeding most cancer driver mutations (typical s ≈ 0.001–0.01).

Cited by mcgranahan2017-clonal-heterogeneity-tumor-evolution as a key example of a “hopeful monster” — a large-effect genomic rearrangement that is occasionally adaptive rather than deleterious. This is the definitive example of a chromothriptic event producing a beneficial rather than oncogenic outcome, directly relevant to chromothripsis, hopeful-monster, clonal-sweep, and punctuated-evolution.

Graph View

Backlinks